{"prompt": "['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE', 'DOCUMENT HISTORY', 'Document', 'Date', 'Amendment 5 (v5.0)', '16 Apr 2020', 'Amendment 4 (v4.0)', '18 Feb 2020', 'Amendment 3 (v3.0)', '28 Aug 2019', 'Amendment 2 (v2.1)', '02 May 2019', 'Amendment 1 (v2.0.0)', '05 Apr 2019', 'Original Protocol (v1.0.0)', '24 Jan 2019', 'Amendment 5 (v5.0; 16 Apr 2020)', 'This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of', 'Directive 2001/20/EC of the European Parliament and the Council of the European Union.', 'Overall Rationale for the Amendment:', 'The primary purpose of this amendment is to enhance monitoring of liver parameters during the', 'conduct of the trial and to provide guidance to address a pandemic or other global health', 'emergencies.', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Section 1.3 Schedule of', 'Addition of Week 5 (Visit 4.25)', 'Week 5 and 6 visits were added', 'Activities;', 'and Week 6 visits (Visit 4.5)', 'to enhance laboratory monitoring', 'Section 1.2 Schema;', 'clinical chemistry panels', 'during the first two months', 'Section 4.1.1 Study Design', 'following IP initiation', 'Section 2.3.1 GB001', 'Updated assessment with recent', 'Updated to clarify risk of liver', 'Benefit/Risk Assessment', 'data', 'injury, critical need for liver', 'monitoring, and low threshold for', 'stopping study drug in cases of', 'suspected liver injury', 'Section 10.6 Appendix 6:', 'Added actions (discontinuation of', 'Clarified discontinuation of IP if', 'Liver Safety - Actions and', 'IP) if labs are not able to be', 'repeat labs could not be obtained', 'Follow-up Assessments', 'confirmed within 48 hours and', 'within 48 hours and re-challenge', 'steps for management of IP re-', 'with investigational product in the', 'challenges', 'case of adverse events of interest', 'Section 10.11 Appendix 11:', 'Added language to address global', 'Clarified that certain adjustments', 'Guidance to Address a', 'health emergencies, eg, COVID-', 'to the protocol may be made in', 'Pandemic or Other Global', '19', 'line with Regulatory Authorities', 'Health Emergencies and', 'Guidance in order to ensure the', 'Potential Impact on the', 'safety of subjects, maintaining', 'Clinical Study', 'compliance with good clinical', 'practice (GCP), and minimizing', '4', 'CONFIDENTIAL']['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'the risks to trial integrity during', 'the COVID-19 pandemic', 'Global Change', 'Minor revisions to text', 'Administrative clarifications were', 'incorporated, and typographical', 'errors were corrected', '5', 'CONFIDENTIAL']['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'TABLE OF CONTENTS', \"SPONSOR'S AUTHORIZED REPRESENTATIVE SIGNATURE PAGE\", '2', 'INVESTIGATOR AGREEMENT', '3', 'PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE', '4', '1.', 'PROTOCOL SUMMARY', '11', '1.1.', 'Synopsis', '11', '1.2.', 'Schema', '13', '1.3.', 'Schedule of Activities', '14', '2.', 'INTRODUCTION', '18', '2.1.', 'Study Rationale', '18', '2.2.', 'Background', '18', '2.3.', 'Benefit/Risk Assessment', '19', '2.3.1.', 'GB001 Benefit/Risk Assessment', '19', '2.3.2.', 'Study Design Benefit/Risk Assessment', '20', '3.', 'OBJECTIVES AND ENDPOINTS', '21', '4.', 'STUDY DESIGN', '23', '4.1.', 'Overall Design', '23', '4.1.1.', 'Study Design', '23', '4.1.2.', 'Unscheduled Visit', '24', '4.2.', 'Scientific Rationale for Study Design', '24', '4.2.1.', 'Study Population', '24', '4.2.2.', 'Choice of Control Group', '25', '4.2.3.', 'Efficacy Endpoint Selection', '25', '4.3.', 'Justification for Dose', '25', '4.4.', 'End of Study Definition', '25', '5.', 'STUDY POPULATION', '26', '5.1.', 'Inclusion Criteria', '26', '5.2.', 'Exclusion Criteria', '26', '5.3.', 'Randomization Criteria', '29', '5.4.', 'Screen or Run-In Failures', '30', '6.', 'INVESTIGATIONAL PRODUCT', '30', '6.1.', 'Investigational Product Administered', '30', '6', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}